The DOI matches its Crossref record.
Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex.
Abstract
The effects of duloxetine (LY248686), a new inhibitor of serotonin (5-hydroxytryptamine; 5-HT) and norepinephrine (NE) uptake on extracellular levels of NE, 5-HT and dopamine (DA), were studied in the rat frontal cortex and nucleus accumbens, using in vivo microdialysis. The oral administration of duloxetine (3.125-12.5 mg/kg) produced a dose-dependent increase in the output of both NE and 5-HT from the frontal cortex, this increase being maintained throughout the 4-hr observation period. Chronic administration of duloxetine (6.25 mg/kg, p.o.) for 14 days failed to alter basal NE and 5-HT levels in the frontal cortex, but augmented the duloxetine-induced increase in output of NE and 5-HT. Amitriptyline and maprotiline, administered p.o. at doses of 6.25 to 25 mg/kg, increased NE output, but the effect was weaker than that of duloxetine, and neither amitriptyline nor maprotiline changed 5-HT output from the frontal cortex. Duloxetine, amitriptyline, and maprotiline brought about increases in DA levels in the rat frontal cortex, the increase in DA levels induced by duloxetine being approximately two or three times more potent than that induced by amitriptyline and maprotiline. In the nucleus accumbens, duloxetine also produced a dose-dependent increase in DA output more potent than that produced by amitriptyline and maprotiline. These results show that duloxetine causes a potent and sustained increase in the output of both NE and 5-HT in the rat frontal cortex, related to its inhibition of NE and 5-HT uptake; these results also show that duloxetine increases DA output in the frontal cortex.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“has been shown to increase extracellular 5-HT, norepinephrine, and dopamine in rat frontal cortex [31]”
Citations
Cited by
Sorted by citations
Items 101–123 of 123
Self-Limited Kleptomania Symptoms as a Side Effect of Duloxetine
Miller, C. W. T., & Gallagher, K. E. (2016) · Case Reports in Psychiatry · doi:10.1155/2016/5472492 · Cited by 4
“, duloxetine, venlafaxine, and milnacipran), which can display dose-dependent activity at different transporters, affecting the serotonin transporter (SERT) at lower doses, the norepinephrine transporter (NET) at intermediate doses, and the dopamine transporter (DAT) at higher doses [4].”
BackgroundKur’yanova, E. V., Zhukova, Y. D., & Теплый, Д. Л. (2017) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-017-3790-2 · Cited by 4
Chemistry and pharmacology of novel antidepressants
Andrews, J. S., & Pinder, R. M. (2001) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8344-3_9 · Cited by 4
Soudijn, W., & van Wijngaarden, I. (1997) · Pharmacochemistry library · doi:10.1016/s0165-7208(97)80019-0 · Cited by 4
Monoamine transporters as continuing targets for drug discovery in depression
Klint, T., & Weikop, P. (2004) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2004.08.014 · Cited by 4
Complex visual disturbances during maprotiline treatment
Yoshino, T., Nisijima, K., Shioda, K., et al. (2012) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2012.02372.x · Cited by 3
“Kihara and Ikeda found an increase in dopamine levels due to maprotiline.(2) Their findings were consistent with those of Carboni et al.”
BackgroundResultComparison of pharmacological profiles of serotonin norepinephrine reuptake inhibitors
Adachi, Y., Aleksić, B., & Ozaki, N. (2010) · Clinical Neuropsychopharmacology and Therapeutics · doi:10.5234/cnpt.1.10 · Cited by 3
“5 mg/kg produced dose-dependent increases in the levels of both 5-HT and NA in the rat frontal cortex [10].”
BackgroundMultifunctional neuroprotective–neurorescue drugs for Parkinson‘s disease
der Schyf, C. J. V., Geldenhuys, W. J., & Youdim, M. B. H. (2007) · Future Neurology · doi:10.2217/14796708.2.4.411 · Cited by 3
“One example of a drug that specifically targets two neuroamine transporter systems, is duloxetine (CymbaltaTM), used in the treatment of depression, which inhibits both serotonin and norepinepherine uptake in the CNS (Figure 1) [30–32].”
BackgroundPharmacotherapy of Major Depressive Disorder: Focus on Duloxetine
Muneoka, K. T. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s1988 · Cited by 3
Preskorn, S., & ROSS, R. W. (2004) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-18500-7_10 · Cited by 3
Shams, S. M. K. (2015) · Journal of Nanomedicine & Nanotechnology · doi:10.4172/2157-7439.1000296 · Cited by 1
“Many published reports showed that there is a significant increase in brain monoamine profile of duloxetine including norepinephrine, serotonin and other chemical neurotransmitters [11,12].”
BackgroundDuloxetine usage in depression
Hu, B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817933-8.00094-3 · Cited by 1
Chapter 6.3 The use of brain microdialysis in antidepressant drug research
Artigas, F., & Adell, A. (2006) · Handbook of behavioral neuroscience · doi:10.1016/s1569-7339(06)16028-2 · Cited by 1
Wpływ escitalopramu, nortryptyliny i wenlafaksyny na objawy bólowe w depresji
Gattner, K. (2014) · Biblioteka Uniwersytetu Medycznego w Poznaniu
(2006) · Wiley eBooks · doi:10.1002/9780470041000.cedt080
Youdim, M. B. H. (2015) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10221
Ding, H., Wang, Y., Gao, Y., Ye, F., Yao, K., Cao, L., Liu, Z., Wang, G., & Zhang, J. (2023) · Research Square · doi:10.21203/rs.3.rs-3793020/v1
Kuramochi, T., Itaya, T., Oshima, Y., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118098
Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine
Trivedi, M. H., Desaiah, D., Ossanna, M. J., Pritchett, Y. L., Brannan, S. K., & Detke, M. J. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f41d7e · Cited by 59
“Duloxetine is relatively balanced in its potency of 5-HT and NE reuptake inhibition (Wong et al., 1993; Kihara and Ikeda, 1995; Kasamo et al., 1996; Bymaster et al., 2001; Bymaster et al., 2005).”
Background
Metadata
- Authors
- Kihara, T., & Ikeda, M.
- Affiliations
- Shionogi (Japan) (JP)
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 1995-01
- Volume
- 272
- Issue
- 1
- Pages
- 177-183
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W1846318813
- Cited by
- 123
- References
- 0
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 4 · 2022: 3 · 2021: 4 · 2020: 2 · 2019: 3 · 2018: 6 · 2017: 3 · 2016: 2 · 2015: 4 · 2014: 5 · 2013: 7 · 2012: 3
- FWCI
- 2.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Pharmacology and Experimental Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- PubMed
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- duloxetine, serotonin-norepinephrine reuptake inhibitors, serotonin, norepinephrine, dopamine, frontal cortex, nucleus accumbens, amitriptyline, maprotiline, chronic drug administration, antidepressant effects
- MeSH terms
- Duloxetine Hydrochloride, Amitriptyline, Animals, Biological Transport, Cerebral Cortex, Dopamine, Male, Maprotiline, Norepinephrine, Nucleus Accumbens, Serotonin, Thiophenes, Rats, Wistar, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
